River Regeneration and Rejuvenation Biotechnology Co. Ltd.

We were established in 2022 as a biotechnology company under the umbrella of Raypal Biomedical which is a subsidiary invested by Compal Electronics Group. 

We focus on utilizing induced Pluripotent Stem Cells (iPSCs) to differentiate into various functional cells such as cardiomyocytes, endothelial cells, etc., and are committed to innovation in the latest technologies. Our mission is to establish a representative cell repository in Taiwan and dedicate ourselves to the research and development of personalized cell therapies, thus promoting the advancement of precision medicine. 

Currently, common cell preparations are typically limited to autologous cell therapy, as they can only be provided for individual use, facing challenges such as the inability to scale production and high costs. To address this challenge, we seek Super Donors whose differentiated cells can be used by most human populations, thus allowing many diseases to be no longer incurable. To ensure users receive high-quality services, we will establish facilities compliant with the international PIC/S GMP standards for cell production. Under the framework of PIC/S GMP, strict control must be exercised over every production step, including the selection and inspection of raw materials, calibration and cleaning of production equipment, and recording and monitoring of formulation processes. We are committed to minimizing the risk of contamination or deterioration of cell products to ensure the quality and safety of the final product.

We are committed to becoming a leader in the field of biopharmaceuticals and will continue to explore and develop innovative technologies and therapeutic approaches to meet the growing medical demands. Furthermore, we will delve deeper into the application of personalized cell therapy, striving to develop more innovative products and solutions that can improve human health. At the same time, we actively participate in international cooperation and academic exchanges, collaborating with top institutions and experts worldwide to jointly promote the development of the biopharmaceutical field.

We firmly believe that through continuous effort and relentless exploration, we will be able to achieve these grand goals and make greater contributions to the health and well-being of humanity.